# A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

> **NCT06510816** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Annexon, Inc.** · enrollment: 659 (actual)

## Conditions studied

- Geographic Atrophy

## Interventions

- **DRUG:** Vonaprument
- **OTHER:** Sham Administration

## Key facts

- **NCT ID:** NCT06510816
- **Lead sponsor:** Annexon, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-30
- **Primary completion:** 2026-10-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 659 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06510816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06510816, "A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06510816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*